1.Clinicopathological Significance of Maspin Expression in Breast Cancer.
Mi Ja LEE ; Chae Hong SUH ; Zhu Hu LI
Journal of Korean Medical Science 2006;21(2):309-314
Maspin is a unique serine proteinase inhibitor that has tumor suppressor activity. It has been reported that maspin is expressed in normal human mammary epithelial cells and it is down-regulated during the progression of cancer. However, to date, there is very limited data on the clinical significance of maspin expression in human breast cancer. In this study, maspin expression was assessed immunohistochemically from 80 invasive ductal carcinoma (IDC) specimens of the breast. Also, maspin expression was compared with the clinicopathological factors (age, grade, tumor size and lymph node status), the expression of estrogen receptor (ER), progesterone receptor (PR) and p53, DNA ploidy and the overall survival in an attempt to assess its prognostic value. The maspin expression was positive in 25 IDC cases (31.3%). The maspin expression in IDC was significantly correlated with a higher histologic grade, a larger tumor size, a positive p53 status and shorter survival. There was an inverse association with maspin expression and the PR status. These findings suggest that maspin expression is not down-regulated with the progression of cancer and maspin expression may be associated with a poor prognosis. The immunohistochemical detection of maspin in breast cancers may be helpful for predicting an aggressive phenotype.
Tumor Suppressor Protein p53/metabolism
;
Survival Rate
;
Serpins/*metabolism
;
Receptors, Progesterone/metabolism
;
Receptors, Estrogen/metabolism
;
Prognosis
;
Ploidies
;
Middle Aged
;
Humans
;
Genes, Tumor Suppressor
;
Female
;
DNA, Neoplasm/analysis/genetics
;
Carcinoma, Ductal, Breast/genetics/*metabolism/mortality/pathology
;
Breast Neoplasms/genetics/*metabolism/mortality/pathology
;
Aged
;
Adult
2.Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females.
Guinian WANG ; Longzi WANG ; Sijing SUN ; Juan WU ; Qinglu WANG
Annals of Laboratory Medicine 2015;35(2):226-232
BACKGROUND: Breast cancer is the most common type of cancer in females. Aberrant expression of microRNA-21 (miR-21) has previously been reported in breast cancer tissue. The aim of this study was to investigate expression levels of serum miR-21 in breast cancer patients and evaluate its prognostic value in Chinese females. METHODS: Real-time quantitative (RQ)-PCR was used to analyze miR-21 expression in archived serum, tumor tissue, and adjacent normal tissue from 549 participants (326 with breast cancer, 223 without breast cancer). We also analyzed associations between serum miR-21 expression and breast cancer subtypes and patient prognosis. Recurrence and survival were analyzed by using the multivariate Cox proportional hazards model. RESULTS: Expression of miR-21 was significantly higher in breast cancer tissues compared with normal adjacent breast tissues (P<0.001). The 2(-DeltaDeltaCt) values for serum miR-21 in breast cancer patients versus healthy controls were 9.12+/-3.43 and 2.96+/-0.73, respectively. Multivariate Cox proportional hazards model suggested that serum miR-21 expression was an independent poor prognostic factor for both recurrence (hazard ratio [HR]= 2.942; 95% confidence interval [CI]=1.420-8.325; P=0.008) and disease-free survival (HR=2.732; 95% CI=1.038-7.273, P=0.003) in breast cancer. CONCLUSIONS: Increased serum miR-21 expression level was correlated with poor prognosis of breast cancer patients, indicating that serum miR-21 may be a novel prognostic marker for recurrence and survival of breast cancer patients before resection.
Biomarkers, Tumor/genetics
;
Breast/metabolism
;
Breast Neoplasms/metabolism/mortality/*pathology
;
Disease-Free Survival
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Lymphatic Metastasis
;
MicroRNAs/*blood
;
Neoplasm Recurrence, Local
;
Prognosis
;
Proportional Hazards Models
;
Real-Time Polymerase Chain Reaction
3.Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.
Eun Sook KO ; Heon HAN ; Boo Kyung HAN ; Sun Mi KIM ; Rock Bum KIM ; Gyeong Won LEE ; Yeon Hee PARK ; Seok Jin NAM
Korean Journal of Radiology 2015;16(5):986-995
OBJECTIVE: To evaluate the relationship between response categories assessed by magnetic resonance imaging (MRI) or pathology and survival outcomes, and to determine whether there are prognostic differences among molecular subtypes. MATERIALS AND METHODS: We evaluated 174 patients with biopsy-confirmed invasive breast cancer who had undergone MRI before and after neoadjuvant chemotherapy, but before surgery. Pathology findings were classified as a pathologic complete response (pCR) or a non-pCR, and MRI findings were designated as a radiologic CR (rCR) or a non-rCR. We evaluated overall and subtype-specific associations between clinicopathological factors including the assessment categories and recurrence, using the Cox proportional hazards model. RESULTS: There were 41 recurrences (9 locoregional and 32 distant recurrences). There were statistically significant differences in recurrence outcomes between patients who achieved a radiologic or a pCR and patients who did not achieve a radiologic or a pCR (recurrence hazard ratio, 11.02; p = 0.018 and recurrence hazard ratio, 3.93; p = 0.022, respectively). Kaplan-Meier curves for recurrence-free survival showed that triple-negative breast cancer was the only subtype that showed significantly better outcomes in patients who achieved a CR compared to patients who did not achieve a CR by both radiologic and pathologic assessments (p = 0.004 and 0.001, respectively). A multivariate analysis found that patients who achieved a rCR and a pCR did not display significantly different recurrence outcomes (recurrence hazard ratio, 2.02; p = 0.505 and recurrence hazard ratio, 1.12; p = 0.869, respectively). CONCLUSION: Outcomes of patients who achieved a rCR were similar to those of patients who achieved a pCR. To evaluate survival difference according to molecular subtypes, a larger study is needed.
Adult
;
Aged
;
Antineoplastic Agents/therapeutic use
;
Breast Neoplasms/drug therapy/mortality/*pathology
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
*Magnetic Resonance Imaging
;
Middle Aged
;
Neoadjuvant Therapy
;
Neoplasm Recurrence, Local
;
Prognosis
;
Proportional Hazards Models
;
Receptor, ErbB-2/genetics/metabolism
;
Receptors, Estrogen/genetics/metabolism
;
Receptors, Progesterone/genetics/metabolism
;
Remission Induction
4.Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy.
Hye Suk HAN ; Jin Soo KIM ; Jin Hyun PARK ; Yoon Kyung JEON ; Keun Wook LEE ; Do Youn OH ; Jee Hyun KIM ; So Yeon PARK ; Seock Ah IM ; Tae You KIM ; In Ae PARK ; Yung Jue BANG
Journal of Korean Medical Science 2009;24(5):910-917
We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as firs-tline chemotherapy in women with HER2-overexpressing metastatic breast cancer (MBC), and we investigated the prognostic factors including magnitude of HER2/neu amplification in this population. We analyzed 54 patients with HER2-overexpressing MBC that were treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy from February 2004 to December 2006. At a median follow-up of 28 months, median time to progression (TTP) was 16.6 months (95% CI, 9.4 to 23.7 months) and median overall survival was 25.6 months (95% CI, 21.8 to 27.3 months). Therapy was generally well tolerated, although three patients (5.5%) experienced reversible, symptomatic heart failure. Of the 27 patients evaluable for the HER2 FISH, patients with a HER2/CEP17 ratio of < or =4.0 had significantly shorter TTP than those with a HER2/CEP17 ratio of >4.0 (10.8 vs. 23.2 months, P=0.034). A HER2/CEP17 ratio of >4.0 was identified as significant predictive factor of TTP by multivariate analysis (P=0.032). The combination of weekly paclitaxel plus trastuzumab as first-line chemotherapy is an effective regimen in patients with HER2-FISH-positive MBC. Furthermore, the magnitude of HER2 amplification is an independent predictive factor of TTP.
Adult
;
Aged
;
Antibodies, Monoclonal/*administration & dosage/therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/therapeutic use
;
Breast Neoplasms/*drug therapy/mortality/pathology
;
Disease Progression
;
Drug Administration Schedule
;
Female
;
Gene Amplification
;
Humans
;
In Situ Hybridization, Fluorescence
;
Middle Aged
;
Paclitaxel/*administration & dosage/therapeutic use
;
Predictive Value of Tests
;
Receptor, erbB-2/*genetics/metabolism
;
Survival Analysis